At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 615 enrolled
Drug / intervention
Desvenlafaxine 100 mg +2 moredrug
Likely dose
Desvenlafaxine 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-controlled Study of MD-120 in Patients With Depression
In Brief
A Phase 3 clinical trial evaluating Desvenlafaxine 100 mg, Desvenlafaxine 50 mg, and 1 other intervention for Major Depressive Disorder. Completed, enrolled 615 participants across 1 site.
Detailed Summary
The purpose of this study is to verify the efficacy and evaluate the safety of 8-week once-daily oral administration of MD-120 in Japanese patients with depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesJapan
CollaboratorsPfizer
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartMay 2020
Primary CompletionJul 2022
Study CompletionSep 2022
TodayJul 2026
First PostedApr 14, 2020
Enrollment StartMay 18, 2020
Primary CompletionJul 21, 2022
Study CompletionSep 14, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.2 years ago
Interventions
Desvenlafaxine 100 mgdrug
once daily dosing for 8 weeks
Desvenlafaxine 50 mgdrug
once daily dosing for 8 weeks
Placebodrug
once daily dosing for 8 weeks